1.229
3.28%
+0.039
After Hours:
1.20
-0.029
-2.36%
Hoth Therapeutics Inc stock is currently priced at $1.229, with a 24-hour trading volume of 29,394.
It has seen a +3.28% increased in the last 24 hours and a -10.29% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.20 pivot point. If it approaches the $1.26 resistance level, significant changes may occur.
Previous Close:
$1.19
Open:
$1.2185
24h Volume:
29,394
Market Cap:
$6.01M
Revenue:
-
Net Income/Loss:
$-9.62M
P/E Ratio:
-0.1976
EPS:
-6.22
Net Cash Flow:
$-7.93M
1W Performance:
+5.04%
1M Performance:
-10.29%
6M Performance:
+0.74%
1Y Performance:
-29.77%
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
646 756 2997
Address
1 Rockefeller Plaza, Suite 1039, New York, NY
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Hoth Therapeutics Inc (HOTH) Net Income 2024
HOTH net income (TTM) was -$9.62 million for the quarter ending September 30, 2023, a +15.40% increase year-over-year.
Hoth Therapeutics Inc (HOTH) Cash Flow 2024
HOTH recorded a free cash flow (TTM) of -$7.93 million for the quarter ending September 30, 2023, a +26.16% increase year-over-year.
Hoth Therapeutics Inc (HOTH) Earnings per Share 2024
HOTH earnings per share (TTM) was -$4.77 for the quarter ending September 30, 2023, a +54.44% growth year-over-year.
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Cap:
|
Volume (24h):